CEPR researches how US government-granted monopolies of patents, copyrights, and other forms of intellectual property redistribute income upward and the role of digital global trade and international commercial agreements on inequality and economic mobility.
CEPR investiga cómo los monopolios de patentes, derechos de autor y otras formas de propiedad intelectual otorgados por el gobierno de los Estados Unidos redistribuyen el ingreso hacia arriba. CEPR analiza el papel del comercio mundial digital y los acuerdos comerciales internacionales sobre desigualdad y movilidad económica.
CEPR researches how US government-granted monopolies of patents, copyrights, and other forms of intellectual property redistribute income upward and the role of digital global trade and international commercial agreements on inequality and economic mobility.
CEPR investiga cómo los monopolios de patentes, derechos de autor y otras formas de propiedad intelectual otorgados por el gobierno de los Estados Unidos redistribuyen el ingreso hacia arriba. CEPR analiza el papel del comercio mundial digital y los acuerdos comerciales internacionales sobre desigualdad y movilidad económica.
· Op-Ed/Commentary
Globalization and TradeIntellectual PropertyWall Street China Did Not Trick the US — Trade Negotiators Served Corporate InterestsDean Baker / August 19, 2019
· Op-Ed/Commentary
GovernmentIntellectual PropertyUS Why Aren’t Democrats Talking About Ending Patent-Financed Drug Research?Dean Baker / July 02, 2019
· Op-Ed/Commentary
Health and Social ProgramsIntellectual PropertyUS Replace Patent Monopolies With Direct Public Funding for Drug ResearchDean Baker / July 01, 2019
· Op-Ed/Commentary
GovernmentIntellectual PropertyUS Would a Compromise on the Drug Pricing Bill Be a Victory or Defeat?Dean Baker / June 03, 2019
· Op-Ed/Commentary
Intellectual PropertyPrivate EquityUSWall Street Can Writers Guild Members Rewrite Private Equity’s Greedy Script?Eileen Appelbaum / April 19, 2019
· report
GovernmentIntellectual PropertyUS The Future of the Pharmaceutical Industry: Beyond Government-Granted MonopoliesDean Baker / March 06, 2019
· Op-Ed/Commentary
Intellectual PropertyUS The Key to Cheap Drugs: Pay Research Costs UpfrontDean Baker / February 18, 2019
· Op-Ed/Commentary
Intellectual PropertyUS Patent Profits and Drug PushersDean Baker / February 17, 2019
· Op-Ed/Commentary
GovernmentIntellectual PropertyUS Warren–Schakowsky Bill Is a Huge Step Toward Bringing Drug Costs DownDean Baker / December 24, 2018
· Op-Ed/Commentary
Health and Social ProgramsIntellectual Property NYT Does Some Mind Reading of Republican Members of Congress on Drug Pricing PolicyCEPR / October 20, 2018
